|
Biosimilars Forum disappointed in FDA guidance
March 2017
SHARING OPTIONS:
WASHINGTON, D.C.—In response to the FDA’s final guidance on nonproprietary naming of biological products, the Biosimilars
Forum recently noted that “While we are pleased that the FDA has finalized the guidance, we are disappointed in their decision to apply meaningless
suffixes in the naming convention for biological drugs. Non-meaningful suffixes will certainly be more difficult for physicians and patients to recall than
meaningful suffixes. Additionally, they will likely lessen the ability to carefully track the identity of the biologic drug administered to patients, thereby
contrary to the stated purpose of having a suffix to enhance pharmacovigilance.
“The introduction of
biosimilars in the U.S. can help expand access to high-quality treatment options for clinicians and patients as well as reduce costs to families, caregivers,
payers and the healthcare systems. Biosimilars are a key free-market solution to lowering drug costs, and we will continue to work with the FDA to advance
these products to the marketplace.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|